home / stock / nrix / nrix articles

NRIX Articles, Nurix Therapeutics Inc.

Stock Information
Company Name: Nurix Therapeutics Inc.
Stock Symbol: NRIX
Market: NASDAQ
Website: nurixtx.com
Menu
NRIX NRIX Quote NRIX Short NRIX News NRIX Articles NRIX Message Board
Get NRIX Alerts

News, Short Squeeze, Breakout and More Instantly...
Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day | Benzinga

SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing t...
Beyond Air, Inc. Reports Q4 Loss, Misses Revenue Estimates | Benzinga

Beyond Air, Inc. (NASDAQ: XAIR) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.47. This comp...

Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday | Benzinga

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...

What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday? | Benzinga

Sunday, Nurix Therapeutics Inc (NASDAQ:NRIX) announced the presentation of updated clinical data for NX-5948, an orally bioavailable degrader of Br...
Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket | Benzinga

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) rose sharply in today's pre-market trading after the company announced results from its ongoi...

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024) | Benzinga

Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clin...

Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024) | Benzinga

SAN FRANCISCO, June 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing t...
Nurix Therapeutics Appoints Paula G. O'Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer | Benzinga

SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing ta...

Nurix Therapeutics Announces Board Chair Transition | Benzinga

David L. Lacey steps down from chair role and will remain board member and retain committee leadership roles Current board member Julia P. Gregory...

Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024) | Benzinga

Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time ...
Next 10